circadian rhythm is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Because the Senate could not muster 60 votes per filibuster rules, funding for non-essential services ended October 1, 2025. Throughout October and into November, Senate had 14 votes, all of which failed to reach the 60-vote threshold. The shutdown ended on November 12. In early October, Senate majority leader John Thune said, "We have a majority of senators — 55 senators have already voted for this clean, short-term, nonpartisan CR," referring to a continuing resolution. Minority Leader Chuck Schumer spoke from the floor of the Senate and said 70% of Americans supported keeping the same money for the Affordable Care Act, informally "Obamacare". In addition, Schumer claimed that a survey by KFF showed that 57% of MAGA supporters also favored keeping the same money for Obamacare. The governments of 25 states sued the Trump administration regarding SNAP benefits ("food stamps") which were expected to run out on the first day of November. 1 out of 8 Americans rely on these benefits. SNAP stands for "Supplemental Nutrition Assistance Program". The administration says that they are prohibited by law from using the "contingency fund" for normal, operational expenses because this money is purposed for extraordinary events such as Hurricane Melissa. The states suing say this both goes against the wording of the law and is a "dramatic change", pointing out that the contingency fund was used for SNAP benefits during the 2019 shutdown.
Indigenous people traded obsidian throughout the Americas. Each volcano and in some cases each volcanic eruption produces a distinguishable type of obsidian allowing archaeologists to use methods such as non-destructive energy dispersive X-ray fluorescence to select minor element compositions from both the artifact and geological sample to trace the origins of a particular artifact. Obsidian cores and blades were traded far inland from the coast. A particularly distant examples of traded obsidian are pieces from the Yellowstone Region found at Hopewell sites, such as Hopewell Culture National Historical Park, Ohio, over 1500 miles away.
==== Shocks ==== Shocks are short-term deviations from long-term trends that have substantial negative effects on a system, people's state of well-being, assets, livelihoods, safety and ability to withstand future shocks. Shocks impacting on agrifood systems may be covariate (an event that directly affects groups of households, communities, regions or even entire countries) or idiosyncratic (an event that affects individuals or households) and include disasters, extreme climate events, biological and technological events, surges in plant and animal diseases and pests, socio-economic crises and conflicts.
=== Japan === The Japanese Liquor Tax Act (ja:酒税法) amendment of April 1981 classifies powdered alcohol as an alcoholic beverage. In the production of powdered alcohol some non-alcoholic ingredients are added which is similar to some liqueurs. Nonetheless, powdered alcohol became a separate category of alcoholic beverages. In May 1981, Sato received the first license to produce alcohol powder commercially. In Japan, powdered alcohol is officially called, funmatsu-shu (ja:粉末酒; lit. 'powdered-alcoholic beverage'). Powdered alcohol is defined by law as a "powdery substance that can be dissolved, and can make a beverage containing 1% or more alcohol by volume". Before the 1981 amendment, powdered alcohol was outside the scope of Liquor Tax, as it is not a liquid.
==== Hypoglycemic unawareness ==== Recurrent episodes of hypoglycemia can lead to hypoglycemic unawareness, or the decreased ability to recognize hypoglycemia. As diabetics experience more episodes of hypoglycemia, the blood glucose level which triggers symptoms of hypoglycemia decreases. In other words, people without hypoglycemic unawareness experience symptoms of hypoglycemia at a blood glucose of about 55 mg/dL (3.0 mmol/L). Those with hypoglycemic unawareness experience the symptoms of hypoglycemia at far lower levels of blood glucose. This is dangerous for a number of reasons. The hypoglycemic person not only gains awareness of hypoglycemia at very low blood glucose levels, but they also require high levels of carbohydrates or glucagon to recover their blood glucose to normal levels. These individuals are also at far greater risk of severe hypoglycemia. While the exact cause of hypoglycemic unawareness is still under research, it is thought that these individuals progressively begin to develop fewer adrenergic-type symptoms, resulting in the loss of neuroglycopenic-type symptoms. Neuroglycopenic symptoms are caused by low glucose in the brain, and can result in tiredness, confusion, difficulty with speech, seizures, and loss of consciousness. Adrenergic symptoms are caused by the body's reaction to low glucose in the brain, and can result in fast heart rate, sweating, nervousness, and hunger. See section above on Signs and Symptoms for further explanation of neuroglycopenic symptoms and adrenergic symptoms.
Sources: en.wikipedia.org
=== Pain === A 2026 meta-analysis concluded that people taking melatonin supplements may experience relief from musculoskeletal pain similar in magnitude to the effects of typical analgesics. Although melatonin may be considered as an adjunct option for pain relief, it had only modest effects, and the quality of evidence for efficacy was low to moderate.
A very large study of 1,028,437 Danish users of various nonsteroidal anti-inflammatory drugs or coxibs found the "Use of the nonselective NSAID diclofenac and the selective cyclooxygenase-2 inhibitor rofecoxib was associated with an increased risk of cardiovascular death (odds ratio, 1.91; 95% confidence interval, 1.62 to 2.42; and odds ratio, 1.66; 95% confidence interval, 1.06 to 2.59, respectively), with a dose-dependent increase in risk." Diclofenac is similar in COX-2 selectivity to celecoxib.
In proper nouns, many Korean monarchs have overly long posthumous names built from many different Sino-Korean nouns describing their positive characteristics, for example Sunjo of Joseon, whose full posthumous name is the 77-syllable-block 순조 선각 연덕현도 경인순희 체성응명흠광석경계천배극융원돈휴의행소윤희화준렬대중지정 홍훈철 모건시태형창 운홍기고명박후강건수정계통수력 공유범문안무정영경 성효대왕 (sunjoseongag-yeondeoghyeondogyeong-insunhuicheseong-eungmyeongheumgwangseoggyeong-gyecheonbaegeug-yung-wondonhyuuihaengsoyunhuihwa-junlyeoldaejungjijeonghonghuncheolmogeonsitaehy-eongchang-unhong-gigomyeongbaghugang-geonsujeong-gyetongsulyeoggong-yubeommun-anmujeong-yeong-gyeongseonghyodaewang). This is simply writing the phrase in Hanja (Hanzi) 純祖先覺淵德顯道景仁純禧體聖凝命欽光錫慶繼天配極隆元敦休懿行昭倫熙化峻烈大中至正洪勳哲謨乾始泰亨昌運弘基高明博厚剛健粹精啓統垂曆建功裕範文安武靖英敬成孝肅皇帝, being transliterate in Hangul. It is not a single word and does not qualify as a lexical entry.
An organelle is a specialized subunit, within a biological cell, that has a specific function. The name organelle comes from the idea that these structures are parts of cells, as organs are to the body, hence organelle, the suffix -elle being a diminutive. Organelles are either separately enclosed within their own lipid bilayers (also called membrane-bound organelles) or are spatially distinct functional units without a surrounding lipid bilayer (non-membrane bounded organelles). Although most organelles are functional units within cells, some functional units that extend outside of cells are often termed organelles, such as cilia, the flagellum and archaellum, and the trichocyst (these could be referred to as membrane bound in the sense that they are attached to (or bound to) the membrane). Organelles are identified by microscopy, and can also be purified by cell fractionation. There are many types of organelles, particularly in eukaryotic cells. They include structures that make up the endomembrane system (such as the nuclear envelope, endoplasmic reticulum, and Golgi apparatus), and other structures such as mitochondria and plastids. While prokaryotes do not possess eukaryotic organelles, some do contain protein-shelled bacterial microcompartments, which are thought to act as primitive prokaryotic organelles; and there is also evidence of other membrane-bounded structures. Also, the prokaryotic flagellum which protrudes outside the cell, and its motor, as well as the largely extracellular pilus, are often spoken of as organelles.
Sources: en.wikipedia.org
==== Alzheimer's disease ==== Active AEP was found at increased levels and translocated to the cytoplasm of neuronal cells of AD patients. In AD the plaques are composed of amyloid beta, intracellular neurofibrillary tangles and tau protein. The dysfunction of APP proteolysis and the abnormal phosphorylation of tau lead to the formation of neuritic plaques and neurofibrillary tangles (NFTs), respectively, causing neuronal degeneration and dementia It also play a crucial role in behavior disorders connected with AD such as anxiety and depression. It also plays a role in stroke. Since stroke elicits acidity in the brain AEP become active due to low pH level. Then it cleaves SET which causes death of brain cells. Targeting of AEP might help to prevent onset of AD symptoms. Development of AEP-selective inhibitors (such as Cbz-L-Ala-L-Ala-AzaAsnchloromethylketone and aza-peptidyl AEP inhibitors) is crucial for helping with diseases.
==== AIDS Relief ==== In the State of the Union address in January 2003, Bush outlined a five-year strategy for global emergency AIDS relief, the President's Emergency Plan for AIDS Relief (PEPFAR). Bush announced $15 billion for this effort, which directly supported life-saving antiretroviral treatment for more than 3.2 million men, women and children worldwide. The U.S. government had spent some $44 billion on the project since 2003 (a figure which includes $7 billion contributed to the Global Fund to Fight AIDS, Tuberculosis, and Malaria, a multilateral organization), which saved an estimated five million lives by 2013. The New York Times correspondent Peter Baker wrote in 2013 that "Bush did more to stop AIDS and more to help Africa than any president before or since." By 2023, PEPFAR was estimated to have saved over 25 million lives, alleviating the severity of the HIV/AIDS epidemic especially in Sub-Saharan Africa, and was called "George W. Bush's greatest accomplishment" by Vox.
=== Comparison with other expression systems === In standard molecular biology research, the bacterium Escherichia coli is the most frequently used organism for expression system, to produce heterologous proteins, due to its features of fast growth rate, high protein production rate, as well as undemanding growth conditions. Protein production in E. coli is usually faster than that in Komagataella, with reasons: Competent E. coli cells can be stored frozen, and thawed before use, whereas Komagataella cells have to be produced immediately before use. Expression yields in Komagataella vary between different clones, so that a large number of clones has to be screened for protein production, to find the best producer. The biggest advantage of Komagataella over E. coli is that Komagataella is capable of forming disulfide bonds and glycosylations in proteins, but E. coli cannot. E. coli might produce a misfolded protein when disulfides are included in final product, leading to inactive or insoluble forms of proteins. The well-studied Saccharomyces cerevisiae is also used as an expression system with similar advantages over E. coli as Komagataella. However Komagataella has two main advantages over S. cerevisiae in laboratory and industrial settings:
A mixer-settler consists of a mixing stage that often forms a suspension of two immiscible liquids followed by a settling stage that allows the liquids to separate into two layers by gravity. Mixer-settlers are typically used when a process requires longer residence times and when the solutions are easily separated by gravity. In a multistage countercurrent process, multiple mixer-settlers are installed in series with the settled output of one stage being fed to subsequent stages for further separation.
Cann, of the University of California, Berkeley, was the first to look at the genetics of mitochondria, passed along the female line; this led to the Mitochondrial Eve theory, who was thought to have lived 200,000 years ago; the new PCR technique allowed strands of hair to be genetically sequenced; Anna Di Rienzo developed the mitochondrial genetics technique at Berkeley, and dated Homo Sapiens to have left Africa around 100,000 years ago; the Cro-Magnon appeared in Eastern Europe 40,000 years ago, who were the first to eat fish; Paul Mellars of University of Cambridge; the Vézère valley in France, with a Cro-Magnon cave, from the upper palaeolithic era; Lawrence H. Keeley at the University of Illinois Chicago; Philip Lieberman and the shape of the human tongue, and impacted molars. Narrated by Gillian Hanna, produced by Ray Fitzwalter, directed by David Hart (both former World in Action executives, which was produced by Granada Television), made by Granada Television. 17 November Teaching Computers to Think, about early machine learning, with John G.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.